Primary splenic diffuse large B-cell lymphoma (PS-DLBCL) is a rare manifestation of malignant lymphoma. Although DLBCL is the most common subtype of non-Hodgkin lymphoma, primary splenic involvement is uncommon. Additionally, a gastrosplenic fistula at initial presentation is even more rare and poses a diagnostic challenge for the radiologist. The clinical and imaging picture can be identical to a splenic abscess with a secondary gastrosplenic fistula formation (GSF), leading to a diagnostic conundrum. Hence, radiologists need to be familiar with this entity for correct diagnosis and appropriate clinical management.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11714051PMC
http://dx.doi.org/10.1016/j.radcr.2024.11.072DOI Listing

Publication Analysis

Top Keywords

primary splenic
12
gastrosplenic fistula
12
splenic diffuse
8
diffuse large
8
large b-cell
8
b-cell lymphoma
8
lymphoma
4
lymphoma presenting
4
presenting gastrosplenic
4
fistula case
4

Similar Publications

Primary splenic diffuse large B-cell lymphoma (PS-DLBCL) is a rare manifestation of malignant lymphoma. Although DLBCL is the most common subtype of non-Hodgkin lymphoma, primary splenic involvement is uncommon. Additionally, a gastrosplenic fistula at initial presentation is even more rare and poses a diagnostic challenge for the radiologist.

View Article and Find Full Text PDF

Multisystemic Sarcoidosis in the Primary Care Setting: A Case Report.

Cureus

December 2024

Family Medicine, Unidade de Saúde Familiar (USF) Amato Lusitano, Unidade Local de Saúde (ULS) de Amadora/Sintra, Amadora, PRT.

Sarcoidosis is a rare, multisystemic disease of unknown etiology, characterized by noncaseating granulomas in various organs. The disease often presents with nonspecific symptoms that complicate the diagnosis. We describe the case of a 31-year-old woman who presented to her family doctor with weight loss, cervical lymphadenopathy, parotid edema, and cutaneous lesions, initially raising suspicion of a lymphoproliferative disorder.

View Article and Find Full Text PDF

Pancreatic cancer is a highly aggressive malignancy with the majority of patients presenting at a late stage with unresectable or metastatic disease. Even with first line treatment, median survival is approximately 11 months in patients with advanced PDAC. This report details the unique case of a patient that presented with peritoneal metastases from an adenocarcinoma of the body of the pancreas, had a remarkable response to palliative chemotherapy and is alive without evidence of disease 12 months following cessation of all active treatment.

View Article and Find Full Text PDF

Objectives The primary objective of this study is to describe and evaluate the diagnostic performance of the hyperdense right hemidiaphragm sign (HRHS) as a novel radiological indicator for diffuse fatty infiltration of the liver on non-enhanced CT (NECT) scans. This includes assessing its sensitivity, specificity, positive predictive value, and negative predictive value, and comparing these metrics with other established NECT signs. Methods This cross-sectional multicenter retrospective study included all patients over 12 years of age who underwent both abdominal MRI and NECT scans of the abdomen within a period not exceeding six months at two tertiary hospitals (The Royal Hospital and Armed Forces Hospital, Muscat, Sultanate of Oman) between January 2010 and December 2022.

View Article and Find Full Text PDF

Enterovirus A71 (EV-A71) has caused hand, foot, and mouth disease with an increased prevalence of neurological complications and acute mortality, threatening young children around the globe. By provoking mucosal immunity, intranasal vaccination has been suggested to prevent EV-A71 infection. However, antigens delivered via the nasal route usually fail to induce a protective memory response.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!